TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31876772

Group type: EXPERIMENTAL
Intervention: SPC placement by vascular access team (VAT) nurses
Number of subjects: 201

Group type: COMPARATOR
Intervention: SPC placement by bedside nurses
Number of subjects: 201
Study: 28800204

Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Endoscope-guided coblation tongue base resection
Number of subjects: 45
Study: 27875489

Group type: EXPERIMENTAL
Intervention: Sliding Hip Screw (SHS)
Number of subjects: 844

Group type: COMPARATOR
Intervention: Intramedullary Nail
Number of subjects: 844
Study: 23647355

Group type: EXPERIMENTAL
Intervention: REDI intervention
Number of subjects: 356

Group type: COMPARATOR
Intervention: Usual practice Head Start
Number of subjects: 356
Study: 23635049

Group type: EXPERIMENTAL
Intervention: Penicillin (250 mg twice a day for 12 months)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Penicillin
Number of subjects: 274
Study: 19268929

Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice a day (group A, 15 subjects)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (group B, 13 subjects)
Number of subjects: 28
Study: 18360062

Group type: EXPERIMENTAL
Intervention: Conventional coronary artery bypass grafting (group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Off-pump surgery (group B)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting with modified, rheoparin coated cardiopulmonary bypass (group C)
Number of subjects: 65
Study: 16789979

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment for 1 year
Number of subjects: 5143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5143

Group type: EXPERIMENTAL
Intervention: Thyroxine treatment
Number of subjects: 5143

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5143
Study: 14510745

Group type: EXPERIMENTAL
Intervention: Gastric-retentive floating tablet administered with three different solid meals
Number of subjects: 0
Study: 10868321

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with varying electrode placement and stimulus intensity
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT) with right unilateral (RUL) electrode placement
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 59
Study: 9124826

Group type: EXPERIMENTAL
Intervention: Cefodizime (2,000 mg as an intravenous bolus; n = 6)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cefpirome (2,000 mg as an intravenous bolus; n = 6)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Fleroxacin (400 mg orally; n = 6)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Dirithromycin (250 mg orally; n = 4)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (4.5 x 10(6) U orally; n = 3)
Number of subjects: 25
Study: 1389343

Group type: EXPERIMENTAL
Intervention: 4‐META adhesive
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: copal varnish
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: dentin bonding agent
Number of subjects: 4

Group type: COMPARATOR
Intervention: control, no liner used
Number of subjects: 4
Study: 3926504

Group type: EXPERIMENTAL
Intervention: Intravenous administration of insulin (0.67 nmol kg‐1 body weight)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (blood taken before insulin administration)
Number of subjects: 6
Study: 31424389

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 309

Group type: COMPARATOR
Intervention: No psychotropic drugs (NO)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: SSRI
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: ANL/BZD
Number of subjects: 309
Study: 29275871

Group type: EXPERIMENTAL
Intervention: Rivaroxaban with aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban without aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27766505

Group type: EXPERIMENTAL
Intervention: Oral supplement of properly balanced omega-3 and omega-6 fatty acids
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Topical cyclosporine treatment
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Combination of omega-3 and omega-6 fatty acids with topical cyclosporine
Number of subjects: 360
Study: 23959782

Group type: EXPERIMENTAL
Intervention: Tea with milk (250 ml black tea plus 50 ml of full fat milk)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Black tea (300 ml)
Number of subjects: 10
Study: 22294639

Group type: EXPERIMENTAL
Intervention: GO‐ON (MW 800‐1500 kD, 25 mg/2.5 ml)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Hyalgan (MW 500‐730 kD, 20 mg/2 ml)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: GO‐ON
Number of subjects: 217
Study: 20165941

Group type: EXPERIMENTAL
Intervention: Colloid fluid loading (gelatin 4%, hydroxyethyl starch 6%, albumin 5%)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline fluid loading (normal saline)
Number of subjects: 48
Study: 18636279

Group type: EXPERIMENTAL
Intervention: Ropivacaine and clonidine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Epidural bupivacaine/morphine/clonidine
Number of subjects: 86
Study: 15958361

Group type: EXPERIMENTAL
Intervention: Selective ET‐A blockade (BQ‐123 alone)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dual ET‐A/B blockade (BQ‐123 and BQ‐788)
Number of subjects: 9
Study: 12610037

Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 452

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Vardenafil (both doses)
Number of subjects: 452
Study: 10625126

Group type: EXPERIMENTAL
Intervention: In-house referral
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: In-house referral (judged to need hospital referral)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Usual referral (control)
Number of subjects: 177
Study: 7795742

Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography (HRCT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Chest Radiography (CR)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HRCT (for subjects with simple silicosis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HRCT (for subjects with conglomerated silicosis)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HRCT (different grades of emphysema)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: HRCT (lowest and highest categories of profusion of parenchymal opacities)
Number of subjects: 27
Study: 1780819

Group type: EXPERIMENTAL
Intervention: Arnica 10(‐30) five pills twice daily for five days, starting the day before the event.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo pills
Number of subjects: 36
Study: 7036147

Group type: EXPERIMENTAL
Intervention: Bezafibrate 200mg every 3rd day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30957675

Group type: EXPERIMENTAL
Intervention: DV ‐ CTA
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional CTA
Number of subjects: 24
Study: 26480029

Group type: EXPERIMENTAL
Intervention: Chairside silica coating with 30 μm SiO2 particles and silanization (Clearfil Porcelain Bond Activator)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 5% hydrofluoric acid etching and silanization
Number of subjects: 192

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: SB-sandblasting with 50 μm Al2 O3 particles
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: ER-etching with an Er:YAG laser (10 W)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: ND-Nd:YAG laser etching (0.8 W)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: FS-etching with a femtosecond laser (860 mW)
Number of subjects: 192
Study: 25331367

Group type: EXPERIMENTAL
Intervention: Standardized preoperative and postoperative strength and endurance exercises and progressive postoperative mobilization, initiated 2 weeks before surgery.
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard regimen comprising regular fast-track principles (Control group).
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Standardized preoperative and postoperative strength and endurance exercises and progressive postoperative mobilization.
Number of subjects: 107
Study: 25166445

Group type: EXPERIMENTAL
Intervention: S‐LANSS score
Number of subjects: 148

Group type: COMPARATOR
Intervention: LANSS and NPQ scores
Number of subjects: 148
Study: 23017815

Group type: EXPERIMENTAL
Intervention: Serial measurement of the cardiovascular biomarker midregion proadrenomedullin (MR‐proADM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical risk scores
Number of subjects: 0
Study: 19237811

Group type: EXPERIMENTAL
Intervention: Risk score for contrast induced nephropathy (CIN) after PCI
Number of subjects: 247
Study: 17519400

Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine qd for 7 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 300 mg tenofovir disoproxil fumarate qd for 7 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days
Number of subjects: 19
Study: 16236942

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dexamethasone (n = 10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 20
Study: 12154258

Group type: EXPERIMENTAL
Intervention: Near-infrared spectroscopic (NIRS) topography
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Stroke patients
Number of subjects: 6
Study: 10202874

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg orally twice daily from the first day of COH until the day of hCG injection)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 7750319

Group type: EXPERIMENTAL
Intervention: Weight loss combined with sleeping on side and nasal spray
Number of subjects: 19
Study: 2316014

Group type: EXPERIMENTAL
Intervention: Fish oil (6 g daily for three months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (6 g corn oil for three months)
Number of subjects: 21
Study: 6270966

Group type: EXPERIMENTAL
Intervention: Adjuvant local radiation therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cyclic treatment with 5‐Fluorouracil, Methotrexate and Chlorambucil
Number of subjects: 37
Study: 30743194

Group type: EXPERIMENTAL
Intervention: Very-low-nicotine-content cigarettes (VLNCCs)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Normal nicotine content cigarettes
Number of subjects: 238
Study: 28257941

Group type: COMPARATOR
Intervention: Simulated altitude at 4300 m
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simulated altitude at 2150 m
Number of subjects: 12

Group type: COMPARATOR
Intervention: Simulated altitude at sea-level
Number of subjects: 12
Study: 25791613

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h on days 1 to 3, followed by 4 mg/24 h on days 4 to 6)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch (2 mg/24 h and 4 mg/24 h)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal patch
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23713936

Group type: EXPERIMENTAL
Intervention: Bagolini striated glasses (BSG)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No Bagolini striated glasses (BSG)
Number of subjects: 52
Study: 21233603

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Definitive Chemoradiation (CRT)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both groups (Surgery and CRT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Surgery and CRT
Number of subjects: 81
Study: 19325138

Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17251316

Group type: EXPERIMENTAL
Intervention: Pharmacy Asthma Care Program (PACP)
Number of subjects: 396

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 396
Study: 15523984

Group type: EXPERIMENTAL
Intervention: CustomCornea
Number of subjects: 93

Group type: COMPARATOR
Intervention: CustomVue
Number of subjects: 93
Study: 11116451

Group type: EXPERIMENTAL
Intervention: Systemic prednisolone mixture 2 mg/kg daily for 5 days
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 9378829

Group type: EXPERIMENTAL
Intervention: CO2 laser with air/water surface cooling
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CO2 laser without air/water surface cooling
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser with air/water surface cooling
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser without air/water surface cooling
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Er:YAG laser with air/water surface coolant
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: S/RP only
Number of subjects: 42

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 42
Study: 1536632

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (symptomatic drugs only)
Number of subjects: 59
Study: 6388521

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31689674

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 1324

Group type: COMPARATOR
Intervention: Non-hysteroscopy
Number of subjects: 1324
Study: 29405867

Group type: EXPERIMENTAL
Intervention: Dating abuse prevention workshop
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 85
Study: 27038012

Group type: EXPERIMENTAL
Intervention: Multi-sensory storytelling (MSST)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Regular storytelling
Number of subjects: 76
Study: 25818931

Group type: EXPERIMENTAL
Intervention: PostCon (ischemic postconditioning)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no ischemic postconditioning)
Number of subjects: 87
Study: 22505744

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo aerosols
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Hot humid air (HA)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Room temperature air (RA)
Number of subjects: 12
Study: 20118012

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol‐remifentanil anesthesia
Number of subjects: 40
Study: 18756603

Group type: EXPERIMENTAL
Intervention: Compression anastomosis clip (CAC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Stapler
Number of subjects: 66
Study: 15916851

Group type: EXPERIMENTAL
Intervention: Platelet activation and fibrinolysis assessment in stroke patients
Number of subjects: 60

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 60
Study: 12671142

Group type: EXPERIMENTAL
Intervention: Postal survey
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Fax survey
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: E-mail survey
Number of subjects: 450

Group type: COMPARATOR
Intervention: Mixed mode survey
Number of subjects: 450
Study: 10098952

Group type: EXPERIMENTAL
Intervention: Transcutaneous nitroglycerine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8542163

Group type: EXPERIMENTAL
Intervention: Ozone exposure (250 ppb)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Filtered air (FA)
Number of subjects: 46
Study: 1871492

Group type: EXPERIMENTAL
Intervention: Immunotherapy by oral route
Number of subjects: 0
Study: 665164

Group type: EXPERIMENTAL
Intervention: Urea and PG F2alpha intra-amniotically
Number of subjects: 10

Group type: COMPARATOR
Intervention: PG F2alpha alone
Number of subjects: 10
Study: 31227397

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tranexamic acid (TXA) 10 mL (100 mg/mL)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of tranexamic acid (TXA)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control group (no TXA injections)
Number of subjects: 304
Study: 27881670

Group type: EXPERIMENTAL
Intervention: Alternate-day caloric restriction (ADCR) with 25% of total energy requirements every other day and 175% of total energy requirements every other day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group with three daily isoenergetic meals
Number of subjects: 20
Study: 26412051

Group type: EXPERIMENTAL
Intervention: ASSIST-linked Brief Intervention (BI)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Simple Advice (SA)
Number of subjects: 236
Study: 23624489

Group type: COMPARATOR
Intervention: CB1 receptor binding in SCZ patients (SCZ-T and SCZ-F)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: CB1 receptor binding in SCZ-F patients
Number of subjects: 67
Study: 21306326

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination (n=93, 259 cycles)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Timed intercourse with clomiphene citrate (n=95, 266 cycles)
Number of subjects: 188
Study: 19801100

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intraoperative dexamethasone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.7 mg/kg intraoperative dexamethasone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 150
Study: 17294139

Group type: EXPERIMENTAL
Intervention: Stenting with predilation
Number of subjects: 58

Group type: COMPARATOR
Intervention: Stenting without predilation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: High cTFC values
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: cTFC
Number of subjects: 58
Study: 15916930

Group type: EXPERIMENTAL
Intervention: Variable-stiffness paediatric colonoscope
Number of subjects: 240

Group type: COMPARATOR
Intervention: Adult colonoscope
Number of subjects: 240
Study: 12837712

Group type: EXPERIMENTAL
Intervention: Antidepressant medication intervention (paroxetine switched to bupropion if lack of response) (n = 88)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Psychotherapy intervention (8 weeks of manual-guided cognitive behavior therapy) (n = 90)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Referral to community mental health services (n = 89)
Number of subjects: 267
Study: 10333940

Group type: EXPERIMENTAL
Intervention: Diagnosis of diabetes based on 2-h glucose load after a 75-g glucose load.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Impaired glucose tolerance assessment.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Hypertension assessment.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Smoking status assessment.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Cholesterol levels assessment in nondiabetic Singaporeans.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: LDL cholesterol assessment.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: HDL cholesterol assessment.
Number of subjects: 3568

Group type: EXPERIMENTAL
Intervention: Triglyceride levels assessment.
Number of subjects: 3568
Study: 7852669

Group type: EXPERIMENTAL
Intervention: Self-management training (7-week program)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 76
Study: 2226538

Group type: EXPERIMENTAL
Intervention: Thrombolysis commenced later than 4-6 hours after symptom onset
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 386

Group type: COMPARATOR
Intervention: sigma ST increases on admission ECG
Number of subjects: 386
Study: 341940

Group type: EXPERIMENTAL
Intervention: Mianserin hydrochloride 20 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Mianserin 20 mg three times daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Desmethylimipramine 25 mg three times daily
Number of subjects: 9
Study: 29175121

Group type: EXPERIMENTAL
Intervention: Elevated unmethylated insulin DNA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elevated methylated insulin DNA
Number of subjects: 0
Study: 27416887

Group type: EXPERIMENTAL
Intervention: Fludrocortisone (50 μg oral dose)
Number of subjects: 21
Study: 24368628

Group type: EXPERIMENTAL
Intervention: AcrySof SA60AT (Group A)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Tecnis ZCB00 (Group B)
Number of subjects: 74
Study: 22867771

Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump therapy (SAPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multiple daily injections of insulin (MDI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SAPT
Number of subjects: 0

Group type: COMPARATOR
Intervention: MDI
Number of subjects: 0
Study: 20858248

Group type: EXPERIMENTAL
Intervention: Patient symptom assessment using EORTC QLQ-C30 version 3
Number of subjects: 1933

Group type: COMPARATOR
Intervention: Provider symptom assessment using corresponding four-point categorical scales
Number of subjects: 1933

Group type: EXPERIMENTAL
Intervention: Agreement assessment between patient and provider scores
Number of subjects: 1933
Study: 18048858

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 1644

Group type: COMPARATOR
Intervention: Endovascular coiling vs Neurosurgical clipping
Number of subjects: 1644
Study: 16132313

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine
Number of subjects: 60
Study: 12271805

Group type: EXPERIMENTAL
Intervention: Cognitive therapy for the prevention of psychosis
Number of subjects: 31

Group type: COMPARATOR
Intervention: Non-patient controls
Number of subjects: 31
Study: 10422602

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 98